Clinical Trial: Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)

U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07923773) titled 'Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)' on Nov. 02.

Brief Summary: The purpose of this 1-year open-label extension study is to characterize the longer-term safety and tolerability of DDY391 and to assess the durability of clinical response in participants with Psoriatic Arthritis (PsA) who have completed treatment in the CDDY391A12201 core study.

Study Start Date: Feb. 10, 2027

Study Type: INTERVENTIONAL

Condition: Moderate to Severe Psoriatic Arthritis

Intervention: DRUG: DDY391

DDY391

Recruitment Status: NOT_YET_RECRUITING

S...